Skip to main content
OpenTrials
Completed

NCT Number: NCT04014673

Natural History Characterization in Symptomatic and Asymptomatic Progranuline Gene Mutation Carriers

The purpose of this study is to investigate whether cognitive deficits, structural and functional changes can be detected before symptom onset in presymptomatic progranuline mutation carriers. The main objectives of the project are to identify novel cognitive, brain imaging markers and peripheral biomarkers for early diagnosis of FTLD, and to follow disease progression.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Groupe Hospitalier Pitié-Salpêtrière - Charles Foix, Paris, France

Loading trial locations.

About this study

The project focuses on the progranulin (PGRN) gene mutation, one of the most frequent genetic forms of frontotemporal dementias (FTD, or frontotemporal lobar degeneration, FTLD). FTD is the second commonest cause of degenerative dementia in presenium after Alzheimer's disease. Behavioral and cognitive impairments progressively lead to dementia. Two major pathological subtypes are now defined in FTD, FTD-TDP and FTD-TAU.

FTD is difficult to detect at an early stage, and no clinical, biological or imaging features can predict the underlying pathology in living patients. Therapeutic perspectives have emerged against tau aggregation, PGRN deficit and C9orf72 expansion. Presymptomatic carriers of genetic FTD would benefit, before onset of symptoms, from these therapeutics that would delay or prevent the disease. At this step, it becomes crucial to develop markers to know how many years before symptoms, the pathological process begins, to treat the patients at the earliest stage of the disease. Markers are also needed to predict the pathology (FTD-TDP/FTD-tau) in patients that will be eligible for trials targeting specific pathological lesion. The main objectives of the project are to identify novel cognitive, brain imaging markers and peripheral biomarkers for early diagnosis of FTLD, and to follow disease progression. Ninety participants including 8 patients and 82 'at-risk' individuals will be recruited and evaluated by clinical partners of the project (Paris, Lille, Rouen, Toulouse, Saint-Etienne, Marseille, Nantes). 'At-risk individuals' are the first- degree relatives of PGRN patients, who have a high a risk (50%) to carry the mutation.

Brain structural changes will be evaluated by voxel-based morphometry (SPM12 software) to assess global brain atrophy in one with the evaluation of atypical shape patterns such as cortical thickness (Freesurfer software) and the study of the cortical sulci (BrainVISA/Morphologist software).

Fluoro Deoxy DGlucose-Positron Emission Tomography (FDG-PET) will allow the identification of brain metabolic markers. Then voxel-based methods using Statistical Parametric Mapping software will be applied to compare different groups or analyze correlations between brain metabolism and cognitive deficits.

The identification of peripheral biomarkers of disease onset and disease progression will take advantage from RNA sequencing, in order to study gene expression and RNA splicing alterations in lymphocytes of patients and 'at risk individuals'.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

for symptomatic patients:

  • Age ≥ 18
  • Signed informed consent for genetic and clinical study
  • To be carrier of a PGRN mutation - Diagnosis criteria of FTD
  • To be affiliated to the social security scheme

Inclusion criteria

for 'at-risk' asymptomatic relatives:

  • Age ≥ 18
  • To be first degree relative of a person carrying a PGRN mutation or first degree relative of FTD deceased patient whose PGRN mutation as been identified in the family
  • Signed informed consent for genetic and clinical study
  • To be affiliated to the social security scheme

Exclusion criteria

Exclusion criteria

for symptomatic patients:

  • Presence of one exclusion criteria from Diagnosis criteria of FTD. - Participation to another therapeutic trial. - Contra-indication to perform a brain MRI and/or PET-FDG
  • Inability to lie one hour without moving
  • Breastfeeding and pregnant women
  • Presence of another intercurrent neurological pathology (vascular cerebral accident, tumor, etc.....)

Exclusion criteria

for 'at-risk' asymptomatic relatives :

  • Presence of neurological or neurodegenerative disease
  • Clinical proven signs of FTD, language disorder, praxis disorder, mnemic, of parkinson's syndrome or amyotrophic lateral sclerosis
  • Contra-indication to perform a brain MRI and/or PET-FDG
  • Inability to lie one hour without moving
  • Breastfeeding and pregnant women
  • Severe vascular lesion , tumor or infectious brain imaging if an MRI was done previously

Treatment and study plan

Behavioral : Characterization

Behavioral

Behavioral scales and neuropsychological tests; MRI, SPECT/PET

Primary outcomes

  1. Rate of change of Frontal Assessment Battery score (/18)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Executive functions changes over time (rate of change in neuropsychological test)

  2. Rate of change of Trail Making Test B-A time (seconds)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Cognitive flexibility changes over time (rate of change in neuropsychological test)

  3. Rate of change of Ekman's faces test score (/35)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Emotional assessment changes over time (rate of change in neuropsychological test)

  4. Rate of change of Faux-pas test score (/35)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Social cognition changes over time (rate of change in neuropsychological test)

  5. Rate of change of Digit span score

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Short-term memory changes over time (rate of change in neuropsychological test)

  6. Rate of change of Free and Cued Selective Reminding test, total recall score (/48)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Long-term memory changes over time (rate of change in neuropsychological test)

  7. Rate of change of Boston Naming test score (/34)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Language changes over time (rate of change in neuropsychological test)

  8. Rate of change of Gestural Praxis battery score (/168)

    Time frame: at baseline 0 Months,at 42 Months, at 72 Months

    Gestural praxis changes over time (rate of change in neuropsychological test)

  9. Rate of change of Neuropsychiatric Inventory score (/144)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Behavioral changes over time (rate of change in neuropsychological questionnaire)

  10. Rate of change of Apathy Evaluation Scale score (/42)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Apathy changes over time (rate of change in neuropsychological questionnaire)

  11. Change in MRI morphological criteria (brain atrophy by voxel-based morphometry)

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

  12. Change in cerebral metabolism by PET (metabolic markers by Fluoro-DeoxyDGlucose-Positron Emission Tomography (FDG-PET))

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

Secondary outcomes

  1. Correlations between cognitive and behavioral scores, MRI morphological criteria, cerebral metabolism by FDG-PET and transcriptome analysis in presymptomatic subjects and in symptomatic patients at early disease stage

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Voxel-based methods using Statistical Parametric Mapping software will be applied to compare different groups or analyze correlations between brain atrophy/metabolism and cognitive deficits.

  2. Differences in transcriptome analysis between symptomatic patients, asymptomatic carriers and controls.

    Time frame: at baseline 0 Months,at 42 Months,at 72 Months

    Study gene expression and RNA splicing alterations in lymphocytes (RNA sequencing)

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: Predict-PGRN

Important dates

Study start
2010
Primary completion
2022
Study completion
2022
First posted
Jul 10, 2019
Registry last updated
Dec 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.